The Oncosearch | Oncotarget

Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts Research Paper

Wei Wei, Song Wu, Xiaolin Wang, Chris Kin-Wai Sun, Xiaoyang Yang, Xinrui Yan, Mei-Sze Chua, Samuel So

Published Jul 10, 2014 · Vol. 5, No. 14 · pp. 5819-5831

Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway Research Paper

Harish Potu, Luke F. Peterson, Anupama Pal, Monique Verhaegen, Juxiang Cao, Moshe Talpaz, Nicholas J. Donato

Published Jun 26, 2014 · Vol. 5, No. 14 · pp. 5559-5569

The MAPK pathway as an apoptosis enhancer in melanoma Research Paper

Johannes M. Haydn, Anita Hufnagel, Johannes Grimm, Katja Maurus, Manfred Schartl, Svenja Meierjohann

Published Jun 8, 2014 · Vol. 5, No. 13 · pp. 5040-5053

GSK-3 as potential target for therapeutic intervention in cancer Review

James A. McCubrey, Linda S. Steelman, Fred E. Bertrand, Nicole M. Davis, Melissa Sokolosky, Steve L. Abrams, Giuseppe Montalto, Antonino B. Dâ€™Assoro, Massimo Libra, Ferdinando Nicoletti, Roberta Maestro, Jorg Basecke, Dariusz Rakus, Agnieszka Gizak, Zoya Demidenko, Lucio Cocco, Alberto M. Martelli, Melchiorre Cervello

Published May 28, 2014 · Vol. 5, No. 10 · pp. 2881-2911

CTGF increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating miR-519d Research Paper

Hsiao-Chi Tsai, Hong-Lin Su, Chun-Yin Huang, Yi-Chin Fong, Chin-Jung Hsu, Chih-Hsin Tang

Published May 21, 2014 · Vol. 5, No. 11 · pp. 3800-3812

The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer Research Paper

Tao Wang, Zhuo Liu, Shuiming Guo, Licheng Wu, Mingchao Li, Jun Yang, Ruibao Chen, Hua Xu, Shaoxin Cai, Hui Chen, Weiyong Li, Liang Wang, Zhiquan Hu, Qianyuan Zhuang, Shaohua Xu, Liping Wang, Jihong Liu, Zhangqun Ye, Jun-Yuan Ji, Chenguang Wang, Ke Chen

Published May 13, 2014 · Vol. 5, No. 11 · pp. 3611-3621

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways Priority Research Paper

Anne Y. Saiki, Sean Caenepeel, Dongyin Yu, Julie A. Lofgren, Tao Osgood, Rebecca Robertson, Jude Canon, Cheng Su, Adrie Jones, Xiaoning Zhao, Chetan Deshpande, Marc Payton, Jebediah Ledell, Paul E. Hughes, Jonathan D. Oliner

Published Apr 23, 2014 · Vol. 5, No. 8 · pp. 2030-2043

PDGFRÎ± up-regulation mediated by Sonic Hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation Research Paper

Francesco Sabbatino, Yangyang Wang, Xinhui Wang, Keith T. Flaherty, Ling Yu, David Pepin, Giosueâ€™ Scognamiglio, Stefano Pepe, John M. Kirkwood, Zachary A. Cooper, Dennie T. Frederick, Jennifer A. Wargo, Soldano Ferrone, Cristina R. Ferrone

Published Mar 31, 2014 · Vol. 5, No. 7 · pp. 1926-1941

Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity Research Paper

Adrienne L. Watson, Bryant J. Keller, Kyle A. Williams, Namrata N. Damle, Samuel J. Finnerty, Leah K. Anderson, Andrew D. Greeley, Vincent W. Keng, Eric P. Rahrmann, Amanda L. Halfond, Natasha M. Powell, Margaret H. Collins, Tilat Rizvi, Christopher L. Moertel, Nancy Ratner, David A. Largaespada

Published Jan 20, 2014 · Vol. 5, No. 6 · pp. 1502-1514

Keywords: Malignant peripheral nerve sheath tumors, plexiform neurofibromas, Schwann cells, neurofibromatosis type 1 syndrome, neurofibromin 1, PI3K/AKT/mTOR signaling, MAPK signaling, targeted therapies, genetically engineered mouse models, combination therapy

Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer Research Paper

Gab-Yong Bae, So-Jung Choi, Ji-Seon Lee, Jisuk Jo, Jinseon Lee, Jhingook Kim, Hyuk-Jin Cha

Published Nov 29, 2013 · Vol. 4, No. 12 · pp. 2512-2522

Keywords: E-Cadherin, EGFR-MEK/ERK signaling, ZEB1, MMP2, Invasion

Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials Research Paper

Ishwaria Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, Aung Naing, Ahmed Kaseb, Javle Milind, Siqing Fu, David S Hong, Sarina Piha-Paul, Jenifer Wheler, Kenneth Hess, Filip Janku, Gerald Falchook, Robert A Wolff, Razelle Kurzrock

Published Jan 27, 2013 · Vol. 4, No. 1 · pp. 153-162

Keywords: Gallbladder Cancer, Cholangiocarcinoma, Phase 1 trials

Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway Research Paper

Guillaume Robert, ValÃ©rie Jullian, Arnaud Jacquel, ClÃ©mence Ginet, Maeva Dufies, Stephanie Torino, AnaÃ¯s Pottier, Frederic Peyrade, Sophie Tartare-Deckert, GeneviÃ¨ve Bourdy, Eric Deharo, Patrick Auberger

Published Dec 30, 2012 · Vol. 3, No. 12 · pp. 1688-1699

Keywords: Simalikalactone E, B-Raf inhibitor, CML, Melanoma, Hairy Cell Leukemia, ERK pathway

Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2 Research Paper

Takayuki Yoshida, Junya Kakegawa, Takayuki Yamaguchi, Yoshiji Hantani, Nobuyuki Okajima, Toshiyuki Sakai, Yoshihiro Watanabe, Motonao Nakamura

Published Dec 1, 2012 · Vol. 3, No. 12 · pp. 1533-1545

Keywords: MEK inhibitor, JTP-74057/GSK1120212/trametinib, chemical probe-affinity chromatography, target identification, unphosphorylated MEK (u-MEK)

Targeting MCT-1 oncogene inhibits Shc pathway and xenograft tumorigenicity Research Paper

Hung-Ju Shih, Hsiao-Huei Chen, Yen-An Chen, Meng-Hsun Wu, Gan-Guang Liou, Wei-Wen Chang, Linyi Chen, Lu-Hai Wang, Hsin-Ling Hsu

Published Nov 9, 2012 · Vol. 3, No. 11 · pp. 1401-1415

Keywords: MCT-1, Shc, Ras, ERK, apoptosis, tumor

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance Review

James Andrew McCubrey, Linda S. Steelman, William H. Chappell, Stephen L. Abrams, Richard A. Franklin, Giuseppe Montalto, Melchiorre Cervello, Massimo Libra, Saverio Candido, Grazia Malaponte, Maria C. Mazzarino, Paolo Fagone, Ferdinando Nicoletti, JÃ¶rg BÃ¤secke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Michele Milella, Agostino Tafuri, Francesca Chiarini, Camilla Evangelisti, Lucio Cocco, Alberto M. Martelli

Published Oct 20, 2012 · Vol. 3, No. 10 · pp. 1068-1111

Keywords: Targeted Therapy, Therapy Resistance, Cancer Stem Cells, Raf, Akt, PI3K, mTOR

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response. Review

James Andrew McCubrey, Linda Steeman, William Chappell, Stephen Abrams, Giuseppe Montalto, Melchiorre Cervello, Ferdinando Nicoletti, Paolo Fagone, Grazia Malaponte, Maria Mazzarino, Saverio Candido, Massimo Libra, Jorg Basecke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Michele Milella, Agostino Tafuri, Lucio Cocco, Camilla Evangelisti, Francesca Chiarini, Alberto Martelli

Published Sep 20, 2012 · Vol. 3, No. 9 · pp. 954-987

Keywords: targeted therapy, therapy resistance, mutations, Raf, Akt, PI3K, mTOR

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon Review

Melchiorre Cervello, James A McCubrey, Antonella Cusimano, Nadia Lampiasi, Antonina Azzolina, Giuseppe Montalto

Published Mar 31, 2012 · Vol. 3, No. 3 · pp. 236-260

Keywords: HCC, signaling pathways, EGF/EGFR, Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR, Wnt/Î²-catenin

Targeting Mnks for Cancer Therapy Review

Jinqiang Hou, Frankie Kam, Christopher G Proud, Shudong Wang

Published Mar 3, 2012 · Vol. 3, No. 2 · pp. 118-131

Keywords: eIF4E, Mnk, Ras, Raf, MAPK, Akt, PI3K, mTOR, Targeted Cancer Therapy, Structure based drug design, Mnk Inhibitors

Cooperative Effects of Akt-1 and Raf-1 on the Induction of Cellular Senescence in Doxorubicin or Tamoxifen Treated Breast Cancer Cells Research Paper

Jackson R. Taylor, Brian D. Lehmann, William H. Chappell, Stephen L. Abrams, Linda S. Steelman, James A. McCubrey

Published Aug 30, 2011 · Vol. 2, No. 8 · pp. 610-626

Keywords: Akt, ERK, mTOR, Senescence, Drug Resistance, Tamoxifen

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers Research Perspective

Ryan B. Corcoran, Jeffrey Settleman, Jeffrey A. Engelman

Published Apr 19, 2011 · Vol. 2, No. 4 · pp. 336-346

Keywords: BRAF, MEK, acquired resistance, melanoma, colorectal cancer, NRAS, IGF1R, PDGFR

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts Research Paper

Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway Research Paper

The MAPK pathway as an apoptosis enhancer in melanoma Research Paper

GSK-3 as potential target for therapeutic intervention in cancer Review

CTGF increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating miR-519d Research Paper

The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer Research Paper

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways Priority Research Paper

PDGFRÎ± up-regulation mediated by Sonic Hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation Research Paper

Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity Research Paper

Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer Research Paper

Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials Research Paper

Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway Research Paper

Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2 Research Paper

Targeting MCT-1 oncogene inhibits Shc pathway and xenograft tumorigenicity Research Paper

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance Review

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response. Review

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon Review

Targeting Mnks for Cancer Therapy Review

Cooperative Effects of Akt-1 and Raf-1 on the Induction of Cellular Senescence in Doxorubicin or Tamoxifen Treated Breast Cancer Cells Research Paper

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers Research Perspective

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts Research Paper

Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway Research Paper

The MAPK pathway as an apoptosis enhancer in melanoma Research Paper

GSK-3 as potential target for therapeutic intervention in cancer Review

CTGF increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating miR-519d Research Paper

The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer Research Paper

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways Priority Research Paper

PDGFRÎ± up-regulation mediated by Sonic Hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation Research Paper

Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity Research Paper

Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer Research Paper

Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials Research Paper

Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway Research Paper

Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2 Research Paper

Targeting MCT-1 oncogene inhibits Shc pathway and xenograft tumorigenicity Research Paper

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance Review

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response. Review

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon Review

Targeting Mnks for Cancer Therapy Review

Cooperative Effects of Akt-1 and Raf-1 on the Induction of Cellular Senescence in Doxorubicin or Tamoxifen Treated Breast Cancer Cells Research Paper

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers Research Perspective